Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

eosinophilic esophagitis (EoE) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

eosinophilic esophagitis

MONDO:0005361

Also known as:EoE

Find Clinical TrialsTrials

Overview

Eosinophilic esophagitis (EoE) is a chronic, allergic disease of the esophagus characterized clinically by symptoms of esophageal dysfunction (including vomiting, dysphagia, feeding disorders, food impaction and abdominal pain) which persist after treatment with proton pump inhibitors (PPIs).

Treatments2 FDA approved, newest 2024

Clinical Trials59 registered · 30 recruiting

Patient Orgs2 organizations · American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED)

Diagnosis

Biomarker and diagnostic research for eosinophilic esophagitis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for eosinophilic esophagitis, including DUPILUMAB (DUPIXENT, approved 2017) and BUDESONIDE (EOHILIA, approved 2024). An additional 12 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

59 clinical trials registered, 30 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and biologic therapy. Pipeline includes 3 PHASE4, 4 PHASE3, 5 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT04653324](https://clinicaltrials.gov/study/NCT04653324)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:21 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

American Partnership for Eosinophilic Disorders (APFED)Primary Focus

USWebsite ↗

Campaign Urging Research for Eosinophilic Disease (CURED)Primary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:73247

Questions for Your Care Team

→What are the benefits and potential side effects of DUPIXENT for managing eosinophilic esophagitis?
→Are any of the 59 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with American Partnership for Eosinophilic Disorders (APFED) and other patient organizations for support?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
regulatory T cell activating peptide	regulatory T cell activating peptide	Revolo Biotherapeutics	2024	—	Designated
tezepelumab	tezepelumab	AstraZeneca Pharmaceuticals LP	2021	—	Designated
Etrasimod L-arginine	Etrasimod L-arginine	Arena Pharmaceuticals, Inc.	2021	—	Designated
technetium-99m radiolabeled heparin	technetium-99m radiolabeled heparin	NexEos Diagnostics, Inc.	2020	—	Designated
Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody	Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody	Allakos, Inc.	2019	—	Withdrawn
benralizumab	benralizumab	AstraZeneca Pharmaceuticals LP	2019	—	Withdrawn
mometasone furoate	mometasone furoate	EsoCap AG	2019	—	Designated
esomeprazole	esomeprazole	Adare Pharmaceuticals US, L.P.	2019	—	Designated
humanized monoclonal antibody targeting interleukin-15	humanized monoclonal antibody targeting interleukin-15	Novartis Pharma AG	2018	—	Designated
fluticasone propionate	fluticasone propionate	Banner Life Sciences, LLC	2015	—	Designated
recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	Celgene Corporation	2015	—	Withdrawn
human monoclonal antibody againt human interleukin 13 (IL-13)	human monoclonal antibody againt human interleukin 13 (IL-13)	Novartis Pharmaceuticals Corporaton	2013	—	Withdrawn

Research Type	Count	% of Total
Research summaries	102	60%
Laboratory research	18	11%
Other research	14	8%
Clinical study results	13	8%
Disease patterns and progression	13	8%
Testing and diagnosis research	5	3%
Patient case studies	5	3%

Kisho

eosinophilic esophagitis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

New data could widen use of AstraZeneca, Amgen immune disease drug

The Relationship Between Eosinophilic Esophagitis and Laryngeal Manifestations: Pathophysiology, Clinical Overlap, and Diagnostic Challenges.

Conservative management of gastroesophageal junction perforation secondary to eosinophilic esophagitis: a case report.

Long-term effectiveness of dupilumab in eosinophilic esophagitis: Results from the DUPEOETALY Study.

eosinophilic esophagitis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

New data could widen use of AstraZeneca, Amgen immune disease drug

The Relationship Between Eosinophilic Esophagitis and Laryngeal Manifestations: Pathophysiology, Clinical Overlap, and Diagnostic Challenges.

Conservative management of gastroesophageal junction perforation secondary to eosinophilic esophagitis: a case report.

Long-term effectiveness of dupilumab in eosinophilic esophagitis: Results from the DUPEOETALY Study.